- Home
- BDTX vs KLRS Comparison
BDTX vs KLRS Comparison
Compare BDTX & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- KLRS
- Stock Information
- Founded
- BDTX 2014
- KLRS 2019
- Country
- BDTX United States
- KLRS United States
- Employees
- BDTX N/A
- KLRS N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BDTX Health Care
- KLRS Health Care
- Exchange
- BDTX Nasdaq
- KLRS Nasdaq
- Market Cap
- BDTX 132.5M
- KLRS 129.0M
- IPO Year
- BDTX 2020
- KLRS N/A
- Fundamental
- Price
- BDTX $2.58
- KLRS $2.50
- Analyst Decision
- BDTX Strong Buy
- KLRS Buy
- Analyst Count
- BDTX 6
- KLRS 1
- Target Price
- BDTX $14.83
- KLRS N/A
- AVG Volume (30 Days)
- BDTX 1.3M
- KLRS 39.9K
- Earning Date
- BDTX 08-05-2025
- KLRS 08-15-2025
- Dividend Yield
- BDTX N/A
- KLRS N/A
- EPS Growth
- BDTX N/A
- KLRS N/A
- EPS
- BDTX 0.09
- KLRS N/A
- Revenue
- BDTX $70,000,000.00
- KLRS N/A
- Revenue This Year
- BDTX N/A
- KLRS N/A
- Revenue Next Year
- BDTX N/A
- KLRS N/A
- P/E Ratio
- BDTX $29.29
- KLRS N/A
- Revenue Growth
- BDTX N/A
- KLRS N/A
- 52 Week Low
- BDTX $1.20
- KLRS $2.28
- 52 Week High
- BDTX $6.75
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- BDTX 60.64
- KLRS N/A
- Support Level
- BDTX $2.43
- KLRS N/A
- Resistance Level
- BDTX $2.72
- KLRS N/A
- Average True Range (ATR)
- BDTX 0.18
- KLRS 0.00
- MACD
- BDTX -0.00
- KLRS 0.00
- Stochastic Oscillator
- BDTX 76.11
- KLRS 0.00
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.